New therapeutic vax targets multiple cancers

Investigators are reporting promising results from their early-stage trial of a new therapeutic cancer vaccine. Scientists say the new vaccine uses an alphavirus to deliver a gene for the carcinoembryonic antigen. Alphaviruses are known to naturally track down dendritic cells, a powerful stimulator of the immune system. In a small human trial involving 28 participants suffering from a variety of late-stage cancers, the vaccine was able to help five of the patients. Story

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.